{
    "clinical_study": {
        "@rank": "114480", 
        "acronym": "ATLANTIS", 
        "arm_group": [
            {
                "arm_group_label": "Asthmatic patients", 
                "description": "asthmatic pats 18 to 65"
            }, 
            {
                "arm_group_label": "Healthy volunteers", 
                "description": "Volunteers 18 to 65"
            }
        ], 
        "biospec_descr": {
            "textblock": "-\tOptional bronchoscopy with endobronchial and trans-bronchial biopsy will be applicable in\n      selected sites only in EU and US. Total number of inflammatory cells and quantification of\n      specific cells including eosinophils, T cells and macrophages will be performed. Gene\n      expression profiles (including RNA) will be performed at a later date for future analysis on\n      the pathobiology of asthma which will be defined in future specific protocols"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "Multinational, multicentre, non-pharmacological intervention, cross-sectional and\n      longitudinal study."
        }, 
        "brief_title": "AssessmenT of smalL Airways involvemeNT In aSthma (ATLANTIS) Multinational, Multicentre, Non-pharmacological Intervention, Cross-sectional and Longitudinal Study.", 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Asthmatic patient inclusion criteria\n\n          1. Male or female patients aged \u2265 18 and \u2264 65 years, who have signed an Informed Consent\n             form prior to initiation of any study-related procedure.\n\n          2. Clinical diagnosis of asthma for at least 6 months confirmed by a chest physician\n             according to international guidelines (GINA 2012) supported by objective evidence of\n             any of the following at the baseline visit or in the previous 5 years.\n\n               1. Positive response to methacholine challenge test [PC20 < 8 mg/mL or PD20 < 0.7\n                  mg for those subjects not using inhaled corticosteroids (ICS), and PC20 < 16\n                  mg/mL or PD20 < 1.4 mg for subjects using ICS] or\n\n               2. Positive response to a reversibility test, defined as \u0394FEV1 \u2265 12% and \u2265 200 mL\n                  over baseline FEV1, within 30 minutes after administration of 400 \u03bcg of\n                  salbutamol pMDI administered with or without Spacer or\n\n               3. Peak Flow variability (i.e. highest - lowest PEF over the day/mean value of the\n                  two, \u00d7 100) > 20%, measured over a follow-up period of 7 days or\n\n               4. Documented response (defined as \u0394FEV1 \u2265 12% and \u2265 200 mL) after a cycle (e.g., 4\n                  weeks) of regular maintenance anti-asthma treatment.\n\n          3. Patients with stable asthma, on any previous regular asthma treatment (\"rescue\"\n             \u03b22-agonists alone included) at a stable dose, for at least 8 weeks prior to baseline\n             visit.\n\n          4. Current smoker, ex-smoker (since the past 12 months) or lifelong non-smoker (total\n             lifetime smoking history < 10 packyears defined as [(number of cigarettes smoked per\n             day) x(number of years of smoking)] / 20).\n\n        Healthy subject inclusion criteria\n\n          1. Male or female patients aged \u2265 18 and \u2264 65 years, who have signed the Informed\n             Consent form prior to initiation of any study-related procedure.\n\n          2. No clinical history of asthma or COPD (no respiratory symptoms compatible to asthma\n             or COPD in the past 2 years).\n\n          3. Current smoker, ex-smoker (since the past 12 months) or lifelong non-smoker (total\n             lifetime smoking history < 10 packyears).\n\n          4. Normal spirometry: baseline FEV1 \u2265 80% of the predicted normal value, FEV1/FVC > LLN\n             (lower limit of normal).\n\n          5. Normal airways responsiveness: PC20 \u2265 16 mg/mL, PD20 \u2265 1.4 mg.\n\n        Asthmatic patient exclusion criteria\n\n          1. Cigarette smoking > 10 packyears defined as [(number of cigarettes smoked per day) x\n             (number of years of smoking)] / 20.\n\n          2. diagnosis of COPD confirmed by a chest physician.\n\n          3. Asthma exacerbation in the 8 weeks prior to baseline visit (defined as a significant\n             deterioration of asthma and signalled by any or more of the following: need for a\n             systemic corticosteroid course (\u2265 3 days); hospitalisation for asthma; emergency room\n             attendance for asthma).\n\n          4. Clinical or functional uncontrolled respiratory, haematological, immunologic, renal,\n             neurologic, hepatic, endocrinal or other disease, or any condition that might, in the\n             judgment of the investigator, compromise the results or interpretation of the study.\n\n          5. Pregnant or lactating women (a urine pregnancy test will be performed).\n\n          6. Participation in an interventional clinical trial with intake of the last dose of any\n             investigational drug <12 weeks preceding baseline visit (last dose < 5 half-lives\n             prior to baseline visit for biologics).\n\n          7. Inability to comply with study procedures.\n\n          8. Alcohol or drug abuse.\n\n        Healthy subject exclusion criteria\n\n          1. Cigarette smoking history > 10 packyears defined as [(number of cigarettes smoked per\n             day) x (number of years of smoking)] / 20.\n\n          2. Diagnosed upper and/or lower respiratory disease(s).\n\n          3. Clinical or functional uncontrolled haematological, immunologic, renal, neurologic,\n             hepatic, endocrinal or other disease, or any condition that might, in the judgment of\n             the investigator, compromise the results or interpretation of the study.\n\n          4. Pregnant or lactating women (a urine pregnancy test will be performed).\n\n          5. Participation in an interventional clinical trial with intake of the last dose of any\n             investigational drug <12 weeks preceding baseline visit (last dose < 5 half-lives\n             prior to baseline visit for biologics).\n\n          6. Inability to comply with study procedures.\n\n          7. Alcohol or drug abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "900 subjects divided into 800 asthmatic patients and 100 healthy controls will be\n        included. Recruitment will be balanced, at the extent possible, in order to achieve at\n        least > 150 patients each for steps 1 - 4 and > 50 patients for step 5 as indicated in the\n        international guidelines (GINA 2012) on the basis of their previous therapy. The 150\n        healthy controls will be recruited on the basis of absence of respiratory symptoms, airway\n        obstruction and hyper responsiveness."
            }
        }, 
        "enrollment": {
            "#text": "900", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02123667", 
            "org_study_id": "CCD-01535AC1-01", 
            "secondary_id": "CCD-01535AC1-01"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 24, 2014", 
        "number_of_groups": "2", 
        "official_title": "Multinational, Multicentre, Non-pharmacological Intervention, Cross-sectional and Longitudinal Study.", 
        "overall_contact": {
            "email": "g.nicolini@chiesi.com", 
            "last_name": "Gabriele Nicolini", 
            "phone": "+39 348 7210679"
        }, 
        "overall_contact_backup": {
            "email": "a.gagnatelli@chiesi.com", 
            "last_name": "Alessandra Gagnatelli, DVM", 
            "phone": "+39 335 8170708"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Italy: The Italian Medicines Agency", 
                "China: Ministry of Health", 
                "United Kingdom: National Health Service", 
                "Spain: Ministry of Health", 
                "Canada: Public Health Agency of Canada", 
                "Brazil: Ministry of Health"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "- To determine the role of small airways abnormalities in the clinical manifestations of asthma.", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02123667"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Chiesi Farmaceutici S.p.A.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chiesi Farmaceutici S.p.A.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}